17 Innovators Highlight Investment to Solve Global Water Challenges
22.3.2023 18:15:00 EET | Business Wire | Press release
Seventeen organizations have joined forces to support the United Nations (UN) Water Action Agenda, pledging to invest $11 billion in water innovation over the next five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005481/en/
Innovators highlight investment to solve global water challenges (Photo: Business Wire)
The collective commitment will be announced later today at an event organized by water technology company Xylem (NYSE: XYL) and the Kingdom of the Netherlands, convened during the UN 2023 Water Conference. The pledges will be included in the Water Action Agenda, a collection of all water-related commitments to accelerate progress on UN Sustainable Development Goal 6 targeting Water and Sanitation.
Executives from Xylem, Veolia, XPV, Hydraloop International, and Hansgrohe will be joined by several nonprofit organizations, to pledge their commitment to invest in innovative water solutions. The funds will be directed toward water-related research and development, start-up companies commercializing innovative approaches to water management, and the deployment of new water technologies. The organizations will also commit to ongoing engagement with development agencies, governments, and other stakeholders to facilitate more cross-sector action to solve water challenges.
“Most of humanity’s challenges today stem from our reliance on water, whether for human life or, on a larger scale, economic well-being and prosperity of society,” said Henk Ovink, Water Envoy of the Kingdom of the Netherlands. “We all need it, but in some places there is too much and in other places there isn’t enough. As significant water investors and users, the private sector has a pivotal role to play. The organizations pledging their commitment today are at the forefront of bringing new innovations to water use, treatment, and recycling. This type of collective action is essential to tackling major water challenges, and to creating a sustainable planet for future generations.”
The commitment from the private and philanthropic sectors to invest in water solutions supports the UN 2023 Water Conference’s call for clear pledges and actions, across all sectors, industries, and interests to achieve the UN Sustainable Development Goals.
“For those who can simply turn on a tap, water may not seem like a problem,” said Patrick Decker, CEO of Xylem. “But the UN 2023 Water Conference is a timely reminder that water challenges are intensifying around the world. The organizations making commitments today recognize these are challenges we can and must solve. Many of the essential technologies already exist, but as climate change progresses, we need more innovative solutions and accelerated implementation to increase the resilience and water-security of communities everywhere.”
The inclusion of the private sector in the UN 2023 Water Conference, the first event of its kind since 1977, has been welcomed as essential in developing an impactful Water Action Agenda. The conference brings together stakeholders from across governments, the private sector, non-governmental organizations, nonprofits, academic institutions, and the scientific community to advance transformative ideas that can solve global water challenges.
Organizations contributing to the pledge include Acciona, Autodesk, BlueTech, Burnt Island Ventures, The Coca-Cola Foundation, Evoqua, Grundfos, Hansgrohe, Hydraloop, Idexx, UGSI Solutions, Veolia, Water Foundry Ventures, Wavin, Westly Group, XPV and Xylem.
The event - Private Sector Investment Commitment to Water Innovation - will convene technology innovators, investors, government, civil society, and development agencies to consider the role of innovation in advancing the UN Sustainable Development Goals. Organized by Xylem and the Consulate General of the Kingdom of the Netherlands in New York, the event will be hosted in partnership with Bluetech Research, Burnt Island Ventures, Evoqua, the International Water Association, Mercy Corps, UNICEF, the Water Foundry, Veolia, the WateReuse Association, and the Water Research Foundation.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005481/en/
Contact information
Houston Spencer
+1 (914) 323-5723
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2026 on July 2 in Munich, Germany. BOT+BAL demonstrated clinically meaningful long-term survival in a heavily pretreated patient population with historically limited benefit from conventional immune checkpoint inhibitors and few durable treatment options after progression on standard therapies. With extended follow-up, median overall survival was 21.2 months and the three-year overall survival rate was 33%, with the Kaplan-Meier curve showing a plateau beyond two years
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 12:12:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to-end AI and cyber exposure assessment engine with a structured execution model that spans from assessment to remediation. At the cor
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 11:00:00 EEST | Press release
Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countries published in “The Allianz 3am Report 2026.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260703907741/en/ Allianz / IPSOS “What Worries the World” Study, April – June 2026. Financial worries, which include concerns about “rising cost of living” (71%) and “insufficient income” (51%), increased in seven out of eight countries surveyed year over year, moving up in the ranking of top three worries in Brazil, France, Germany, and the U.K., while remaining stable in Italy. The strongest increases are observed in Australia and Indonesia, where financial concerns have remained the leading worry, as well
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 09:40:00 EEST | Press release
Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in Tokyo on July 6, 2026. Fusion energy has the potential to shift the foundation of energy from natural resources to advanced technology by reproducing, on Earth, the sam
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 08:15:00 EEST | Press release
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class of payloads for antibody-drug conjugates. The company's platform is built around next-generation N-myristoyltransferase inhibitor (NMTi) payloads, a differentiated mechanism of action designed to address the narrow therapeutic windows and tolerability challenges that have limited earlier generations of ADCs, such as TOPO-1 and tubulin inhibitor payload classes. Myricx Bio's two lead ADC assets, directed towards the established targets B7-H3 and HER2, are designed to bring this differentiated approach to patients across a broad ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom